Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Split-Course Bridging Radiotherapy Prior To Commercial CD19 CAR T-Cell Therapies For Patients With Relapsed or Refractory B-Cell Lymphomas
NCT05574114Phase 1Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Oct 2022
- Primary completion
- Oct 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in non-Hodgkin lymphoma (NHL), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Number of patients who develop unanticipated severe toxicity events at 1 year. Started Oct 2022; status: active, not recruiting.
02
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT05574114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05574114.